Latest News and Press Releases

MENLO PARK, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) announced today that its stockholders approved all of the proposals presented at the Annual...

MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the second quarter ended June 30, 2017 and provided an update...

-- Phase 1 clinical trial will evaluate the effect of ipilimumab and evofosfamide (TH-302) in advanced solid tumors -- -- Company management to host “Hypoxia and Immunotherapy” conference call today...

- Definitive merger agreement between Threshold and Molecular Templates expected to close mid-2017 - - Initiation of the Phase 1 clinical trial of evofosfamide in combination with ipilumumab at the...

-- Recently proposed merger with Molecular Templates will result in Nasdaq-listed company focused on developing novel treatments for cancer -- SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE...

-- Transaction to result in Nasdaq-listed company focused on developing novel treatments for cancer -- -- Molecular Templates lead drug candidate being developed to treat non-Hodgkin’s Lymphoma...

-- Preclinical studies will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia cancer cell lines with high AKR1C3 expression -- SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 ...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today...

-- Planning to initiate a clinical trial of evofosfamide in combination with checkpoint inhibitors -- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc....

-- Tarloxotinib Primary Interim Response Rate Endpoint Achieved in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (SCCS) but not Achieved in Patients with Metastatic...